P
PAVmed Inc. (PAVM)
NCM – Real vaqt narxi. Valyuta: USD
6.50
-0.25 (-3.70%)
Yopilishda: May 12, 2026, 4:00 PM EDT
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
Find any stock by ticker or company name
NCM – Real vaqt narxi. Valyuta: USD
6.50
-0.25 (-3.70%)
Yopilishda: May 12, 2026, 4:00 PM EDT
PAVmed Inc. Qo'shma Shtatlarda javob berilmagan ehtiyojlarga qaratilgan yangi mahsulotlarni sotib olish, ishlab chiqish va tijoratlashtirish bilan shug'ullanadi. Kompaniyaning asosiy mahsulotlari orasida CarpX, karpal tunnel sindromini davolash uchun patenti bo'lgan, bir martalik, bir marta ishlatiladigan, minimal invaziv jarrohlik moslamasi; EsoCheck Esophageal Cell Collection Device, bu diagnostik test bo'lib, u oshqozonning prekanseroz holatini erta aniqlash orqali oshqozon adenokarsinomasi o'limini oldini olish uchun sinov vositasi bo'lib xizmat qiladi, bu esa oshqozon-jarohatlashuv reflyuks kasalligi, jumladan surunkali yonish va kislotali reflyuks yoki oddiygina bemorlarda reflyuksni o'z ichiga oladi; va EsoCheck moslamasi bilan to'plangan oshqozonning yuzaki hujayralarida o'tkaziladigan bisulfitga aylantirilgan keyingi avlod ketma-ket DNK tahlili EsoGuard mavjud. Mahsulotlar qatorida disbastik BE ni davolash uchun EsoCure Esophageal Ablation Device; PortIO, implantatsiya qilinadigan intraosseoz tomir kirish moslamasi; va Veris saratonni davolash platformasi ham mavjud. Kompaniya ilgari PAXmed Inc. nomi bilan tanilgan va 2015 yil aprel oyida PAVmed Inc. deb o'zgartirgan. PAVmed Inc. 2014 yilda ro'yxatga olingan va Nyu-York, Nyu-Yorkda joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Brian J. deGuzman M.D. | Executive VP, Chief Technology & Compliance Officer |
| Dr. Deepika A. Lakhani Ph.D. | Senior VP, Chief Regulatory & Quality Officer |
| Dr. Lishan Aklog M.D. | Chairman & CEO |
| Dr. Suman M. Verma M.D., Ph.D. | Senior VP of Molecular Genetics & Chief Scientific Officer |
| Dr. Victoria T. Lee M.D. | Executive Vice President & Chief Medical Officer |
| Mr. Joseph Virgilio |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-04-30 | DEF 14A | formdef14a.htm |
| 2026-04-21 | S-3 | forms-3.htm |
| 2026-04-02 | S-8 | forms-8.htm |
| 2026-03-30 | 8-K | form8-k.htm |
| 2026-03-27 | 10-K | pavm20251231_10k.htm |
| 2026-02-24 | DEF 14A | formdef14a.htm |
| 2026-02-17 | D | |
| 2026-02-13 | PRE 14A | formpre14a.htm |
| 2026-02-04 | 8-K | form8-k.htm |
| 2026-01-23 | 8-K | form8-k.htm |
| SVP & Chief Business Officer of Medical Devices |
| Mr. Matthew Riley | Senior Director of Investor Relations |
| Mr. Michael Adam Gordon | Executive VP, General Counsel & Secretary |
| Mr. Shaun M. O'Neill M.B.A. | Executive VP & COO |